Myeloma Minute: Healthcare Cost Disruptors
|
| INNOVATION | Dr. Durie's Blog
New Amazon Project to Rethink Health Care Could Defy the SkepticsCan Amazon, Berkshire Hathaway, and JPMorgan Chase disrupt our costly healthcare system? IMF Chairman Dr. Brian G.M. Durie is hopeful about the prospect. “Like all of us, they don’t want to stand idly by and do nothing — no matter how difficult,” he says.
|
|
|
| ACTION | Fundraiser
|
| ACTION | Fundraiser
|
Great Wine + Great Causes |
A Journey Into the Five Senses |
|
Brady and Christen Raanes’ (c)3 Wines sources grapes from the best vineyards in the world, with the mission of passing all profits to charitable organizations. Purchase a bottle and profits will benefit the IMF. Cheers! |
Accomplished artist Claudia Meyer hosts her solo art show “Sensoria” at the Castelli Art Space at 5440 W. Washington Blvd. in Los Angeles from February 3-11, 2018. A portion of all sales of her works from this event will benefit the IMF. |
|
|
|
|
| EMPOWERMENT | Give Today
February 4 Is World Cancer DayCancer knows no borders. In 2013, the IMF founded the Global Myeloma Action Network to improve the lives of myeloma patients around the world. Support the IMF this World Cancer Day to fight myeloma globally.
| INNOVATION | Latest Research
Phase II Results of Selinexor Plus Low-Dose Dexamethasone PublishedThe publication of the phase II results with selinexor plus low-dose dexamethasone is a step forward for this first-in-class oral agent. This combination has an overall response rate of 21% in heavily pretreated patients, also known as quad-refractory (patients previously treated with four drugs) and penta-refractory (patients treated with five drugs, including daratumumab). These results satisfy an “unmet need” category that improve chances of FDA approval. Even though selinexor plus low-dose dex has some side effects, including low blood counts and fatigue, this regimen may become an important addition to available myeloma therapies.
FDA Clears Hydrashift 2/4 Daratumumab Assay for TestingThe FDA approved the use of Hydrashift 2/4 daratumumab assay for evaluating response in multiple myeloma patients treated with Darzalex® (daratumumab). Darzalex, a fully human monoclonal antibody that binds to CD38, may interfere with immunofixation results in MM patients. The Hydrashift 2/4 daratumumab assay mitigates such interference in immunofixation test results.
|
|
|
| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series
|
|
CLINICAL TRIALS |
EVENTS |
|
New selinexor STORM Trial: Learn How to Participate New ARROW Clinical Trials: Learn How to Participate New ixazomib Clinical Trials: Learn How to Participate Join the conversation about myeloma on the Smart Patients Message Board |
Listen to a Replay: Best of ASH 2017 teleconference February 3, 2018 February 9-10, 2018 February 25, 2018 March 10, 2018 March 16-17, 2018 April 21, 2018
|
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year